Oxybutynin R-isomer

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 121065

CAS#: 119618-21-2 (free base)

Description: Oxybutynin R-isomer, also known as Aroxybutynin, is a muscarinic receptor antagonist. Aroxybutynin is the optically avtice inhibitor of proliferation and supresses gene expression in bladder smooth muscle cells. Oxybutynin exerts direct antispasmodic effect on smooth muscle and inhibits the muscarinic action of acetylcholine on smooth muscle. It exhibits one-fifth of the anticholinergic activity of atropine on the rabbit detrusor muscle, but four to ten times the antispasmodic activity. No blocking effects occur at skeletal neuromuscular junctions or autonomic ganglia (antinicotinic effects).

Chemical Structure

img
Oxybutynin R-isomer
CAS# 119618-21-2 (free base)
Instruction

Theoretical Analysis

MedKoo Cat#: 121065
Name: Oxybutynin R-isomer
CAS#: 119618-21-2 (free base)
Chemical Formula: C22H31NO3
Exact Mass: 357.23
Molecular Weight: 357.490
Elemental Analysis: C, 73.92; H, 8.74; N, 3.92; O, 13.43

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 5633-20-5 (racemate)   1508-65-2 (racemate HCl)   1207344-05-5 (R-isomer HCl)   119618-21-2 (R-isomer)   2862851-81-6 (R-isomer tartrate)   2738613-22-2 (R-isomer citrate)   119618-22-3 (S-isomer)   230949-16-3 (S-isomer HCl),  

Synonym: Oxybutynin; Aroxybutynin; (-)-Oxybutynin; (R)-Oxybutynin; MJ4309-1; MJ-4309-1; MJ 4309-1;

IUPAC/Chemical Name: 4-(diethylamino)but-2-yn-1-yl (R)-cyclohexyl(hydroxy)(phenyl)acetate

InChi Key: XIQVNETUBQGFHX-QFIPXVFZSA-N

InChi Code: InChI=1S/C22H31NO3/c1-3-23(4-2)17-11-12-18-26-21(24)22(25,19-13-7-5-8-14-19)20-15-9-6-10-16-20/h5,7-8,13-14,20,25H,3-4,6,9-10,15-18H2,1-2H3/t22-/m0/s1

SMILES Code: CCN(CC)CC#CCOC([C@](C1CCCCC1)(O)C2=CC=CC=C2)=O

Appearance: To be determined

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 357.49 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Capalbo D, Guarino S, Di Sessa A, Esposito C, Grella C, Papparella A, Miraglia Del Giudice E, Marzuillo P. Combination therapy (desmopressin plus oxybutynin) improves the response rate compared with desmopressin alone in patients with monosymptomatic nocturnal enuresis and nocturnal polyuria and absence of constipation predict the response to this treatment. Eur J Pediatr. 2023 Jan 25. doi: 10.1007/s00431-023-04824-5. Epub ahead of print. PMID: 36693995.


2: Molinelli E, D'Agostino GM, Sapigni C, Gioacchini H, Brisigotti V, Rizzetto G, Offidani A, Simonetti O. Oral oxybutynin chloride therapy in the management of hidradenitis suppurativa: A prospective study. J Eur Acad Dermatol Venereol. 2023 Jan 22. doi: 10.1111/jdv.18901. Epub ahead of print. PMID: 36682048.


3: Aishah A, Loffler KA, Toson B, Mukherjee S, Adams RJ, Altree TJ, Ainge-Allen HW, Yee BJ, Grunstein RR, Carberry JC, Eckert DJ. One Month Dosing of Atomoxetine plus Oxybutynin in Obstructive Sleep Apnea: A Randomized, Placebo- controlled Trial. Ann Am Thorac Soc. 2022 Dec 20. doi: 10.1513/AnnalsATS.202206-492OC. Epub ahead of print. PMID: 36538809.


4: Attallah HS, El-Gilany AH, Youssef YEB, Abdelshaheed ME, Sharaf EFA. Efficacy, Safety and Quality of Life of Oxybutynin versus Aluminum Chloride Hexahydrate in Treating Primary Palmar Hyperhidrosis. Indian J Dermatol. 2022 May-Jun;67(3):222-227. doi: 10.4103/ijd.IJD_799_20. PMID: 36386101; PMCID: PMC9644765.


5: Edwards BA, Joosten SA. Variability in the response to atomoxetine and oxybutynin for OSA: Highlighting the need for personalized medicine. Respirology. 2023 Mar;28(3):215-216. doi: 10.1111/resp.14395. Epub 2022 Oct 18. PMID: 36257913.


6: Kinouchi T, Terada J, Sakao S, Koshikawa K, Sasaki T, Sugiyama A, Sato S, Sakuma N, Abe M, Shikano K, Hayama N, Shiko Y, Ozawa Y, Ikeda S, Suzuki T, Tatsumi K. Effects of the combination of atomoxetine and oxybutynin in Japanese patients with obstructive sleep apnoea: A randomized controlled crossover trial. Respirology. 2023 Mar;28(3):273-280. doi: 10.1111/resp.14383. Epub 2022 Oct 2. Erratum in: Respirology. 2022 Oct 30;: PMID: 36184258.


7: Malik MF, Randall JH, Campbell JG, McLaughlin MJ, Koenig JF. Dosing Variability and Clinical Outcomes of Oxybutynin: A Pediatric Cohort of Patients With Neurogenic Bladder. Top Spinal Cord Inj Rehabil. 2022 Summer;28(3):9-14. doi: 10.46292/sci21-00091. Epub 2022 Aug 17. PMID: 36017125; PMCID: PMC9394069.


8: Sun P, Wang Z, Wu T, Zuo S, Huang X, Cui Z, Zhang D. Injectable, Adhesive, and Self-Healing Composite Hydrogels Loaded With Oxybutynin Hydrochloride for the Treatment of Overactive Bladder in Rats. Front Bioeng Biotechnol. 2022 Jun 27;10:906835. doi: 10.3389/fbioe.2022.906835. PMID: 35832402; PMCID: PMC9272884.


9: Dothan D, Raisin G, Malchi N, Gordon A, Touitou D, Chertin B. Intravesical sustained release system of lidocaine and oxybutynin results from in vitro and animal study. Int Urol Nephrol. 2022 Sep;54(9):2167-2174. doi: 10.1007/s11255-022-03280-8. Epub 2022 Jul 3. PMID: 35780464.


10: Messineo L, Loffler K, Chiang A, Osman A, Taranto-Montemurro L, Eckert DJ. The Combination of Betahistine and Oxybutynin Increases Respiratory Control Sensitivity (Loop Gain) in People with Obstructive Sleep Apnea: A Randomized, Placebo-Controlled Trial. Nat Sci Sleep. 2022 Jun 7;14:1063-1074. doi: 10.2147/NSS.S362205. PMID: 35698591; PMCID: PMC9188336.


11: Sheng Y, Zhang S, Ling J, Hu C, Zhang Z, Lv H. Oxybutynin nanosuspension gel for enhanced transdermal treatment for overactive bladder syndrome. Pharm Dev Technol. 2022 Apr;27(4):459-468. doi: 10.1080/10837450.2022.2078983. Epub 2022 May 24. PMID: 35575444.


12: Schweitzer PK, Maynard JP, Wylie PE, Emsellem HA, Sands SA. Efficacy of atomoxetine plus oxybutynin in the treatment of obstructive sleep apnea with moderate pharyngeal collapsibility. Sleep Breath. 2022 May 13:1–9. doi: 10.1007/s11325-022-02634-x. Epub ahead of print. PMID: 35551600; PMCID: PMC9098382.


13: Dwyer J, Tafuri SM, LaGrange CA. Oxybutynin. 2022 Apr 25. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan–. PMID: 29763161.


14: Marthi S, Pomerantz MA, Mernan AJ, Berlow YA. The Twilight Zone: Oxybutynin Overuse Exacerbating Delirium. J Geriatr Psychiatry Neurol. 2022 Nov;35(6):840-845. doi: 10.1177/08919887221090215. Epub 2022 Apr 6. PMID: 35383492.


15: Shen SH, Jia X, Peng L, Zeng X, Shen H, Luo DY. Intravesical oxybutynin therapy for patients with neurogenic detrusor overactivity: a systematic review and meta-analysis. Int Urol Nephrol. 2022 Apr;54(4):737-747. doi: 10.1007/s11255-022-03129-0. Epub 2022 Feb 28. PMID: 35226282.


16: Norris JJ, Raj JP, Thomas TT, Maleperambil TT, Shubha AM. Effects of oxybutynin in children with posterior urethral valves post fulguration: Report in a select cohort of children. J Family Med Prim Care. 2021 Oct;10(10):3706-3711. doi: 10.4103/jfmpc.jfmpc_2554_20. Epub 2021 Nov 5. PMID: 34934669; PMCID: PMC8653479.


17: Jaworski P, Mello GF, Ferreira GM, Oliveira MH, Fraga R. Mirabegron as effective as oxybutynin for ureteral stent symptoms. Rev Assoc Med Bras (1992). 2021 Dec;67(12):1793-1797. doi: 10.1590/1806-9282.20210711. PMID: 34909951.


18: Yosrey E, Elmansi H, Sheribah ZA, El-Sayed Metwally M. Factorial design- assisted spectroscopic determination of oxybutynin hydrochloride. R Soc Open Sci. 2021 Nov 24;8(11):211027. doi: 10.1098/rsos.211027. PMID: 34849244; PMCID: PMC8611342.


19: Cirino LMD, Vergne DMC, Novais GB, Cano A, Padilha FF, Severino P, de Albuquerque Júnior RLC, Cardoso JC, Souto EB. Liposomal formulations of oxybutynin and resiniferatoxin for the treatment of urinary diseases: improvement of drug tolerance upon intravesical. Drug Deliv Transl Res. 2022 Jul;12(7):1738-1752. doi: 10.1007/s13346-021-01082-6. Epub 2021 Oct 20. PMID: 34671947.


20: Perger E, Taranto Montemurro L, Rosa D, Vicini S, Marconi M, Zanotti L, Meriggi P, Azarbarzin A, Sands SA, Wellman A, Lombardi C, Parati G. Reboxetine Plus Oxybutynin for OSA Treatment: A 1-Week, Randomized, Placebo-Controlled, Double-Blind Crossover Trial. Chest. 2022 Jan;161(1):237-247. doi: 10.1016/j.chest.2021.08.080. Epub 2021 Sep 20. PMID: 34543665.